SAB Biotherapeutics surges after flu treatment meets study goal

SAB Biotherapeutics

01/12/2021 12:56

** Shares of drug developer  SABS.O  rise 14.3% to $12.45
premarket
    ** Co says its experimental treatment for seasonal influenza
met the main and secondary goals of a mid-stage study (https://refini.tv/3I3NnhL)
    ** The drug, SAB-176, achieved statistically significant
reductions in viral load and clinical signs and symptoms
compared to placebo
    ** Study, initiated in June 2021, tested safety and
treatment efficacy of SAB-176 in 60 healthy adults challenged
with a pandemic influenza virus strain
    ** Data suggest SAB-176 has the potential to be an effective
treatment for this virus that resurfaces annually and is a major
source of hospitalizations and deaths - CEO
    ** SAB plans to further evaluate SAB-176 in a mid-stage
influenza clinical trial slated to begin in 2Q 2022

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))